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Risk of atrophy in kidneys with atherosclerotic renal artery stenosis.
The goal of this study was to determine the incidence of and risk factors
for renal atrophy among kidneys with atherosclerotic renal artery stenosis
(ARAS). Participants with at least one ARAS were followed prospectively
with duplex scans performed every six months. Renal atrophy was defined
as a reduction in renal length of greater than 1 cm. A total of 204 kidneys
in 122 subjects were followed for a mean of 33 months. The two-year
cumulative incidence (CI) of renal atrophy was 5.5%, 11.7%, and
20.8% in kidneys with a baseline renal artery disease classification of
normal, , 60% stenosis, and $ 60% stenosis, respectively (P 5 0.009, log
rank test). Other baseline factors associated with a high risk of renal
atrophy included a systolic blood pressure . 180 mm Hg (2-year CI 5
35%, P 5 0.01), a renal artery peak systolic velocity . 400 cm/second
(2-year CI 5 32%, P 5 0.02), and a renal cortical end diastolic velocity
# 5 cm/second (2-year CI 5 29%, P 5 0.046). The number of kidneys
demonstrating atrophy per participant was correlated with elevations in
the serum creatinine concentration (P 5 0.03). In patients with ARAS,
there is a significant risk of renal atrophy among kidneys exposed to
elevated systolic blood pressure and among those with high-grade ARAS
and low renal cortical blood flow velocity as assessed by renal duplex
scanning. The occurrence of renal atrophy is well-correlated with changes
in the serum creatinine concentration.
The term “ischemic nephropathy” refers to the gradual loss of
kidney function associated with severe occlusive disease of the
extraparenchymal renal artery. Although the role of renal artery
stenosis as a cause of secondary hypertension has been known
since the report by Goldblatt in 1934, the relationship between
renal ischemia and renal insufficiency has been appreciated only
recently [1–3]. It has been estimated that atherosclerotic renal
artery occlusive disease is the primary cause of end-stage renal
failure in 5% to 15% of patients over the age of 50 years who
begin dialysis each year [4, 5].
The role of surgical revascularization versus renal artery angio-
plasty and stenting for this condition is in evolution. Given that
renal artery occlusive disease can result in a loss of renal mass, the
challenge is to intervene at a stage when the ischemic changes are
still reversible, or perhaps before they have even taken place.
However, the exact relationship between the degree of renal
artery narrowing and the risk of subsequent loss of renal mass is
not known. Furthermore, the role of other putative risk factors for
renal atrophy (such as age, diabetes, and hypertension) in persons
with renal artery stenosis (RAS) has not been well-characterized.
Because duplex ultrasound is non-invasive and provides accu-
rate information on the degree of diameter reduction in the renal
artery, the length of the kidney, and the blood flow velocity in the
renal parenchyma, it is an excellent tool for prospective assess-
ment of the effects of ischemia on renal size. The goal of this study
was to use serial renal duplex scanning to better characterize the
risk of renal atrophy in kidneys with atherosclerotic renal artery
stenosis (ARAS).
METHODS
In January of 1990, we began a prospective study to examine the
natural history of renal artery stenosis using duplex ultrasonogra-
phy. Participants were recruited into this study if they had at least
one stenotic or occluded renal artery by duplex scanning and were
not considered candidates for immediate intervention. Subjects
were recruited from several medical centers and clinics in the
Puget Sound area. The initial indication for renal artery screening
was hypertension, azotemia, or both. The referring physicians
have included internists, family practitioners, nephrologists, and
vascular surgeons. During the course of this study, the patient’s
primary care and/or referring physicians continued to manage all
aspects of care including blood pressure medication and the
decision to intervene upon a stenotic renal artery. This study was
approved by the Human Subjects Review Committee at the
University of Washington and informed consent was obtained
from all participants.
Exposure assessment
Recruited subjects were seen in the vascular research labora-
tory at the University of Washington every six months for
examination and blood draw. The technique of renal artery duplex
scanning has been described previously [6–8]. All examinations
were performed by one of two technologists using an ATL
Ultramark 9 or HDI duplex scanner (Advanced Technology
Laboratories, Bothell, WA, USA). After an overnight fast, sub-
jects were examined in the supine position using either a 2.25 or
1 See Editorial by Toto, p 794.
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3.2 MHz phased array or a 3 MHz mechanical sector transducer.
The abdominal aorta was examined first and the aortic peak
systolic velocity (PSV) was measured at the level of the superior
mesenteric artery. Velocities were then measured in the origin,
proximal, middle, and distal segments of each renal artery. The
angle between the Doppler ultrasound beam and the renal artery
was # 60 degrees for all renal artery velocity measurements. The
renal artery PSV (RAPSV) was the highest PSV measured in the
renal artery. The renal-aortic ratio (RAR) is defined as the
RAPSV divided by the aortic PSV. The severity of stenosis in the
renal artery was classified according to previously-validated crite-
ria as follows: (1) normal (RAPSV , 180 cm/second); (2) , 60%
stenosis (RAPSV $ 180 cm/second, RAR , 3.5 cm/second); (3)
$ 60% stenosis (RAR $ 3.5 cm/second); and (4) occluded (no
velocity signals obtainable).
The renal cortical peak systolic (CPSV) and end diastolic
velocities (CEDV) were measured in the arcuate arteries of the
renal cortex. These measurements were made with either a 2 or 10
mm sample volume, and a zero degree angle between the Doppler
ultrasound beam and the vessel axis. For each cortical velocity
parameter, an average of two measurements (made at the supe-
rior and inferior renal poles) was used for the analysis. The end
diastolic ratio (EDR), which is a measure of renal parenchymal
resistance, is the peak systolic velocity divided by the end diastolic
velocity. It can be measured anywhere in the renal artery or
kidney from ostium to cortex. For this analysis, an average of four
measurements in the renal parenchyma (medulla and cortex,
superior and inferior poles) was used.
Blood pressure was measured at each visit using a stethoscope
and sphygmomanometer in the supine position after at least 15
minutes of rest. The blood pressure determination used for the
analysis was an average of two measurements made on the arm
with the higher blood pressure. The ankle arm index (AAI) was
also measured at each visit using a continuous-wave Doppler. The
AAI is the ankle systolic pressure (the higher of the anterior vs.
posterior tibial arteries) divided by the higher of the brachial
systolic pressures. For the purposes of the analysis, we used the
leg with the lowest AAI.
Beginning in January of 1990, blood was drawn and tested for
serum creatinine concentration at the baseline visit. The creati-
nine concentration was also determined at every other follow-up
visit (annually) for the first two years, and then at every follow-up
visit (every 6 months) after January of 1992. Beginning in August
of 1994, blood was also drawn for lipid analysis including total, low
density lipoprotein (LDL), and high density lipoprotein (HDL)
cholesterol concentrations. All blood draws were performed after
an overnight fast.
Outcome assessment
The aim of this study was to assess the incidence of and risk
factors for renal atrophy in persons with atherosclerotic RAS. The
pole-to-pole renal length as assessed by B-mode ultrasound was
used to estimate renal parenchymal mass in this study. Three
renal length measurements were performed per kidney during
most examinations. In cases where more than one length mea-
surement was made, the mean of these measurements was used as
the renal length for the analysis. The lateral decubitus approach
was most frequently used to image the kidney, but the anterior
coronal or posterior approaches sometimes provided a better
view, especially in obese persons.
Renal atrophy was defined as a reduction in renal length of
greater than 1 cm during follow-up compared to the length at the
baseline examination. The 1 cm threshold was based on the
between-observation variability for renal length measurement in
this study which was 0.55 cm. This number was obtained by
performing a simple linear regression of renal length as a function
of time for all the kidneys in this study. The SD of all points about
the regression lines was 0.39 cm, which yielded a between-
observation variability of 0.55 cm (0.39 3 21/2) that was not
affected by linear trends in renal length over time. A reduction in
measured length of greater than 1 cm was thus unlikely (P 5 0.03,
1-tailed analysis) in the absence of a true size change.
It was clear that some of the kidneys in our natural history study
had already shrunk and/or had occluded renal arteries at the time
of study entry. The decision was made to limit this study to those
kidneys that had not yet demonstrated any appreciable atrophy at
the time of the baseline examination. Since the “normal” pole-to-
pole renal length as measured by B-mode ultrasound is 11 cm with
a SD of 1.25 cm [9], we excluded all kidneys with baseline lengths
less than 8.5 cm (11 cm minus 2 SD). There were a total of 18
occluded renal arteries at the time of the baseline examination in
the natural history study. The mean baseline renal length for this
group of kidneys was 7.2 cm (6 1.3 cm). Kidneys with occluded
arteries at baseline were excluded from this analysis because of
their small size and because they are generally not considered to
be amenable to revascularization.
We presumed that the renal length would be a poor estimate of
parenchymal renal mass in kidneys with either large or multiple
cysts. The decision was made a priori to exclude all kidneys with
large ($ 4 cm) renal cysts. Cysts less than 2 cm in diameter were
not consistently detected and did not appear to affect the length
measurement. Cysts between 2 and 4 cm did appear to affect the
length determination, especially when multiple in number or
when located at the poles. Kidneys having cysts in this size range
were excluded if there were more than two or if they were located
at the poles.
Kidneys were not excluded from the analysis if an intervention
had been performed on the ipsilateral renal artery prior to study
entry. When intervention was performed during the study, all
subsequent examinations were excluded from the analysis. Since a
minimum of one follow-up examination was required for inclusion
in this study, all kidneys having arteries that were intervened upon
between the baseline examination and the first follow-up exami-
nation were excluded from this analysis.
Study population
For this analysis, there were a total of 151 participants for
whom there was at least one follow-up examination. Two partic-
ipants were removed from the analysis because they had missed
several follow-up visits. An additional 11 subjects were removed
because the presumed etiology of their RAS was fibromuscular
dysplasia. Two persons had unilateral nephrectomies before the
beginning of the study. This left a total of 274 potential kidneys in
138 subjects. Of these, 70 kidneys were removed from the analysis
for the following reasons: 28 because of the presence of either
large or multiple cysts; 21 because of the presence of either renal
artery occlusion or size , 8.5 centimeters at the baseline exami-
nation; 18 because of intervention performed on the renal artery
between the baseline examination and the first follow-up exami-
nation; and 3 because the duplex examinations were too difficult
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to obtain meaningful data. The remaining 204 kidneys in 122
subjects form the basis of this report.
Statistical analysis
The data analysis was performed using SPSS for Windows,
version 6.1. The time to detection of a greater than one centimeter
reduction in renal length was modeled using the Cox proportion-
al-hazards method. Each of the continuous factors that demon-
strated a strong association with renal atrophy were stratified into
four roughly equal sized groups and the cumulative incidence of
renal atrophy in these groups was then assessed with the Kaplan-
Meier method and statistical significance was assessed using the
logrank test. This stratification allowed us to determine which
levels of a given factor were associated with particularly high risk.
The strongest individual predictors of renal atrophy were assessed
in a Cox proportional-hazards model with multiple predictors in
order to control for confounding. Due to possible dependence of
renal atrophy between left and right kidneys within a study
subject, the standard errors and P values of the Cox model
coefficients and the log rank P values were calculated using the
jackknife method with the patient as the unit of observation [10].
Finally, changes in the serum creatinine concentration over time
were assessed using simple linear regression and the mean change
was assessed as a function of the number of kidneys (per
participant) demonstrating atrophy during the study.
RESULTS
There were a total of 204 kidneys (100 left and 104 right sides)
in 122 participants followed for a mean of 33 months (range, 5 to
72 months). There were a total of 692 duplex examinations
performed on these 122 subjects. Table 1 shows the baseline
characteristics of the study participants. The mean blood pressure
at baseline was 163 (6 23)/84 (6 10) mm Hg; 95% of the
participants were treated with at least one anti-hypertensive
medication and 26% were treated with at least three medications
for their blood pressure.
Table 2 shows the baseline characteristics of the 204 kidneys in
the study as assessed by duplex ultrasound. The range of baseline
renal lengths was very close to what would be expected in an age-
and sex-matched population of persons without RAS [9], as we
excluded kidneys that had demonstrated any appreciable atrophy
at the baseline examination. Participants had a broad range of
renal artery occlusive disease because subjects were included if
they had either one or two renal arteries with at least a , 60%
stenosis.
A reduction in renal length of greater than one centimeter was
detected in 33 (16.2%) of the 204 kidneys during the study. Figure
1 shows the cumulative incidence of renal atrophy stratified
according to the baseline disease classification. The cumulative
incidence (CI) of atrophy at two years following the baseline
examination was: 5.5% for kidneys with normal baseline renal
arteries; 11.7% among kidneys having arteries with , 60%
stenosis; and 20.8% for kidneys having $ 60% stenosis at base-
line. This association was statistically significant (P 5 0.009, log
rank test).
Renal artery occlusion was detected in five arteries during this
study. All of these arteries were classified as having $ 60%
stenosis at the baseline examination, and all five kidneys supplied
by these arteries shrank . 1 cm during follow-up. The lengths of
these kidneys measured at the examination prior to occlusion
were 8.2, 8.5, 9.0, 9.1, and 9.2 cm.
Table 3 shows the univariate Cox proportional hazards analysis
of risk factors for renal atrophy. Three baseline factors were
strongly associated with the subsequent risk of renal atrophy:
systolic hypertension, severity of renal artery stenosis, and dimin-
ished renal cortical blood flow velocity. Each 20 mm Hg increase
in baseline SBP was associated with a 2.1-fold increase in risk for
renal atrophy (P 5 0.003). We studied several variables that are
surrogates for the severity of renal artery stenosis including
RAPSV, RAR, and renal artery disease class, all three variables
Table 1. Baseline characteristics of study participants
Characteristic Statistic Value N subjects
Total # subjects 122
Demographics
Age in years mean 6 SD 68 6 9 122
Gender percent male 45% 122
Blood pressure
Systolic blood pressure
in mm Hg
mean 6 SD 163 6 23 122
Diastolic blood pressure
in mm Hg
mean 6 SD 84 6 10 122
Lipids
Total cholesterol mg/dl mean 6 SD 218 6 37 100
LDL cholesterol mg/dl mean 6 SD 130 6 37 100
HDL cholesterol mg/dl mean 6 SD 50 6 19 100
Diabetes percent 16% 122
Body mass index mean 6 SD 25 6 6 111
Cigarette smoking
Former percent 57% 122
Current percent 23% 122
Serum creatinine mg/dl mean 6 SD 1.6 6 2.0 121
Lowest ankle arm index mean 6 SD 0.96 6 0.23 122
Past medical history
Myocardial infarction percent 32% 122
Stroke percent 9% 122
On ACE inhibitor percent 34% 121
Abbreviations are: LDL, low density lipoprotein; HDL, high density
lipoprotein; ACE, angiotensin converting enzyme.
Table 2. Baseline characteristics of kidneys in the study population
Characteristic Statistic Value
N
kidneys
Number of kidneys 204
Length of follow-up months mean (range) 33 (5–72) 204
Renal length cm mean (range) 10.8 (8.8–14.5) 204
Severity of renal artery
stenosis
RAPSV cm/sec mean 6 SD 296 6 141 204
Renal-aortic ratio mean 6 SD 4.0 6 2.0 204
Renal artery disease class
Normal percent 21% 204
,60% stenosis percent 30% 204
$60% stenosis percent 49% 204
Renal cortical blood flow
CPSV cm/sec mean 6 SD 20.5 6 7.7 204
CEDV cm/sec mean 6 SD 6.8 6 2.5 204
EDR mean 6 SD .32 6 0.07 203
Accessory renal artery
identified
percent 9% 204
Abbreviations are: RAPSV, renal artery peak systolic velocity; CPSV,
cortical peak systolic velocity; CEDV, cortical end diastolic velocity; EDR,
end diastolic ratio.
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demonstrated statistically significant associations with subsequent
renal atrophy. The RAPSV showed the strongest association with
renal atrophy (P 5 0.0009) with each 100 cm/sec increase corre-
sponding to a 1.5-fold increase in risk. Both CPSV and CEDV
were associated with increased risk for renal shrinkage, and the
CEDV was more predictive (P 5 0.005). The use of angiotensin-
converting enzyme (ACE) inhibitors at baseline showed no sig-
nificant association with renal atrophy, even among kidneys with
high-grade stenosis. Finally, the identification of an accessory
renal artery was not associated with a decreased risk of renal
atrophy, as one might have predicted.
The mean blood pressure during follow-up examinations was
also associated with the occurrence of renal atrophy. The mean
follow-up SBP was $ 140 mm Hg for 75% and $ 160 mm Hg for
38% of the subjects, and the mean DBP was $ 90 mm Hg for 10%
of the participants. The Cox regression analysis predicted a
1.9-fold increase in the risk of atrophy associated with each 20 mm
Hg increase in SBP (P 5 0.009) and a 1.6-fold increase in the risk
of atrophy associated with each 10 mm Hg increase in DBP (P 5
0.04).
Figures 2 to 4 show the CI of renal atrophy through two years
stratified according to the baseline levels of SBP, RAPSV, and
CEDV, respectively. In each case, the factor was stratified into
four roughly equal-sized groups to determine which levels were
associated with particularly high risk for renal shrinkage. The
pattern was quite similar for each of these variables. There were
moderate increases in the risk of renal atrophy associated with
increasing levels of SBP and RAPSV, and then a large increase in
risk for the highest levels of these parameters. Similarly, there
were only small increases in the risk of renal atrophy associated
with diminishing levels of CEDV, but a large increase in risk
associated with the lowest level of CEDV. The CI of renal atrophy
at two years for the highest-risk groups in these categories was
35.0% for SBP . 180 mm Hg, 32.0% for RAPSV . 400
cm/second, and 28.8% for CEDV # 5 cm/second.
One might predict a high degree of covariation between SBP,
RAPSV and CEDV as high-grade renal artery stenosis (reflected
by the RAPSV) is known to cause hypertension and diminished
Fig. 1. Cumulative incidence of renal atrophy
stratified according to baseline renal artery
disease classification (DZ Class). Standard
error is , 10% through 24 months for all plots.
Symbols are: () $ 60% stenosis; (E) , 60%
stenosis; (f) normal. P 5 0.009, log rank test.
Table 3. Cox proportional hazards analysis of association between
baseline factors and risk of renal atrophy
Factor/comparison groups N kidneys RR 95% CI
Demographics
Age, per 10 year increase 204 1.5 (0.9,2.6)
Gender, male sex vs. female 204 1.1 (0.5,2.4)
Blood pressure
Systolic blood pressure, per 20 mm Hg
increase
204 2.1b (1.3,3.5)
Diastolic blood pressure, per 10 mm Hg
increase
204 1.2 (0.8,1.7)
Lipids
Total cholesterol, per 30 mg/dl increase 164 1.3 (0.9,2.0)
LDL cholesterol, per 30 mg/dl increase 164 1.5 (0.9,2.4)
HDL cholesterol, per 20 mg/dl decrease 164 1.1 (0.7,1.8)
Diabetes, diabetic vs. not 204 1.3 (0.4,4.3)
Body mass index, per 5 unit increase 187 0.8 (0.6,1.3)
Current cigarette smoking, yes vs. no 204 0.6 (0.1,2.8)
Serum creatinine, per 1 mg/dl increase 203 1.0 (0.5,2.2)
Ankle arm index, per 0.15 unit decrease 204 1.1 (0.9,1.4)
ACE inhibitor, taking vs. not 202 1.1 (0.5,2.5)
Renal length, per 1 cm increase 204 1.1 (0.7,1.7)
Severity of renal artery stenosis
RAPSV, per 100 cm/sec increase 204 1.5c (1.2,1.9)
Renal-aortic ratio, per 1 unit increase 204 1.2a (1.0,1.4)
Renal cortical blood flow
CPSV, per 5 cm/sec decrease 204 1.7a (1.0,2.7)
CEDV, per 2 cm/sec decrease 204 2.1b (1.3,3.6)
EDR, per 0.05 unit decrease 204 1.2 (0.9,1.6)
Accessory renal artery, not identified vs.
identified
204 0.8 (0.3,2.3)
Abbreviations are: RR, relative risk; RAPSV, renal artery peak systolic
velocity; CPSV, cortical peak systolic velocity; CEDV, cortical end dia-
stolic velocity; EDR, end diastolic ratio.
a P , 0.05, b P , 0.01, c P , 0.001
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renal cortical blood flow. Indeed, when these variables were
evaluated simultaneously using the Cox proportional hazards
model (Table 4), there was moderate confounding as evidenced
by the diminution in the relative risk estimates after adjustment.
Even after adjustment however, each baseline factor maintained a
marginally or statistically significant association with subsequent
renal atrophy, indicating that each factor contributed indepen-
dently to the prediction of renal shrinkage in this study popula-
tion. There was no significant modification among SBP, RAPSV,
and CEDV in predicting subsequent renal atrophy based on both
the evaluation of stratified Kaplan-Meier plots and on the use of
interaction terms in the Cox model.
Finally, there was a statistically significant association between
the number of kidneys per participant that became atrophic
Fig. 2. Cumulative incidence of renal atrophy
stratified according to baseline systolic blood
pressure (SBP in mm Hg). Standard error is
, 10% through 24 months for all plots.
Symbols are: () .180 mm Hg; (E) 161 to 180
mm Hg; (f) 141 to 160 mm Hg; (L) # 140
mm Hg. P 5 0.01, log rank test.
Fig. 3. Cumulative incidence of renal atrophy
stratified according to baseline renal artery
peak systolic velocity (RAPSV in cm/sec).
Standard error is , 10% through 24 months for
all plots. Symbols are: () . 400 cm/sec; (E)
251 to 400 cm/sec; (f) 181 to 250 cm/sec; (L)
#) 180 cm/sec. P 5 0.02, log rank test.
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during this study and the observed change in the serum creatinine
concentration (Table 5). The mean change in serum creatinine
concentration was 1 0.08 mg/dl per year among participants with
atrophy detected in one kidney and 1 0.33 mg/dl per year among
those with atrophy detected in both kidneys.
DISCUSSION
There are relatively few reports in the literature dealing with
the problem of decreasing kidney size in patients with renal artery
stenosis. In a study by Dean et al, changes in renal function were
evaluated in 41 patients with renovascular hypertension who were
followed from 6 to 84 months on medical treatment [11]. A
decrease in kidney size greater than 10% was noted on serial
intravenous pyelograms in 37% of the patients. Schreiber, Pohl
and Novick retrospectively examined kidney length changes that
were associated with arteriographic progression of renal artery
disease [12]. A decrease in kidney size was defined as a greater
than 1.5 cm difference in pole-to-pole measurements on serial
X-rays. Thirty-seven of 85 patients (44%) with atherosclerotic
renal artery stenosis demonstrated disease progression, and 26
(70%) of these 37 patients showed a significant decrease in kidney
size.
The studies summarized above involved small numbers of
highly selected patients who were identified after invasive diag-
nostic tests had been performed for specific clinical indications. In
contrast, natural history studies are based on frequent follow-up
of consecutive or randomly selected persons with a particular
condition; arteriography and invasive functional studies are not
Fig. 4. Cumulative incidence of renal atrophy
stratified according to baseline cortical end
diastolic velocity (CEDV in cm/second).
Standard error is , 10% through 24 months for
all plots. Symbols are: () 0 to 5 cm/second;
(E) 5.1 to 6.5 cm/second; (f) 6.6 to 8
cm/second; (L) . 8 cm/second. P 5 0.046, log
rank test.
Table 4. Cox proportional hazards analysis of the risk of renal atrophy
associated with systolic blood pressure, renal artery peak systolic
velocity, and renal cortical end diastolic velocity
Covariates in model RR 95% CI P value
SBP, per 20 mm Hg increase
Alone 2.1 (1.3,3.5) 0.003
Adjusted for RAPSV 2.0 (1.1,3.4) 0.02
Adjusted for CEDV 1.9 (1.0,3.6) 0.06
Adjusted for RAPSV and CEDV 1.8 (0.9,3.6) 0.1
RAPSV, per 100 cm/sec increase
Alone 1.5 (1.2,1.9) 0.0009
Adjusted for SBP 1.4 (1.1,1.7) 0.008
Adjusted for CEDV 1.4 (1.1,1.8) 0.004
Adjusted for SBP and CEDV 1.3 (1.1,1.7) 0.02
CEDV, per 2 cm/sec decrease
Alone 2.1 (1.3,3.6) 0.006
Adjusted for SBP 1.7 (1.0,3.1) 0.06
Adjusted for RAPSV 2.0 (1.2,3.5) 0.01
Adjusted for SBP and RAPSV 1.7 (0.9,3.1) 0.1
Abbreviations are: RR, relative risk; SBP, systolic blood pressure;
RAPSV, renal artery peak systolic velocity; CEDV, renal cortical end
diastolic velocity.
Table 5. Mean change in the serum creatinine concentration per year
stratified by the number of kidneys (per subject) in which atrophy was
detected
N kidneys
demonstrating
atrophy N subjectsa
Mean D [Creat]/year
mg/dl per year P valueb
0 86 10.01 —
1 19 10.08 0.4
2c 7 10.33 0.03
[Creat] is creatinine concentration.
a 112 of 122 patients had $2 creatinine determinations during the study
permitting linear regression to be performed.
b P 5 0.03 for the test for a linear trend between creatinine concentra-
tion change and number of shrinking kidneys; listed P values are for t-tests
with “0 shrinking kidneys” as the referent category
c One subject in this group had one kidney that shrank during the study
contralateral to an atrophic kidney at baseline
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suitable for this purpose. The emergence of renal duplex scanning
as an accurate noninvasive method for assessing both the renal
artery and renal parenchyma has made detailed natural history
studies of renal artery disease possible [7, 8, 13, 14].
Early experience with serial duplex scanning in our laboratory
showed that a significant decrease in renal length correlates with
the presence of severe ipsilateral renal artery stenosis [15].
Because of the larger sample size in the present study, we were
able to better characterize the relationship between the degree of
renal artery stenosis and the risk of atrophy, and we were also able
to examine the importance of other potential risk factors.
A small kidney is a common finding in patients with chronic
atherosclerotic renal artery occlusion [16]. Indeed, the 18 kidneys
excluded from this analysis because of renal artery occlusion at
baseline were quite small. However, progression to renal artery
occlusion was not a major contributing factor to the renal atrophy
observed in this study. Only 5 of the 33 kidneys that shrank during
this study developed occluded renal arteries during follow-up.
Furthermore, since all five kidneys were less than 9.5 cm in length
at the examination prior to renal artery occlusion, it is likely that
some atrophy had taken place as a result of severe renal artery
stenosis before occlusion.
The atrophic changes that occur in the setting of renal ischemia
have been well-documented in several animal models [17–21].
The histologic changes depend on the degree of impairment of
renal perfusion and include findings ranging from glomerular and
tubular atrophy in kidneys with moderate ischemia to arteriolar
hyalinization, glomerular and interstitial necrosis and fibrosis with
more severe reductions in renal perfusion [18]. In this study, we
quantified the degree of renal ischemia at the baseline examina-
tion using two parameters: the severity of renal artery stenosis as
estimated by the RAPSV and the velocity of blood flow in the
renal cortex. We found that RAPSVs greater than 400 cm/second
and CEDVs less than or equal to 5 cm/second were associated
with particularly high risk of renal atrophy. Both factors had
predictive values, even after controlling for the level of the other
parameter.
The pathologic evaluation of ischemic human kidneys is more
complicated than in animal models owing to the presence of other
factors that are associated with renal atrophy such as age,
hypertension, and diabetes [22]. The renal lesions associated with
these conditions include various types of glomerulosclerosis and
tubulointerstitial damage leading to regional cortical scarring. In
this study, we found a strong association between systolic hyper-
tension and subsequent renal atrophy, and this association was
still present even after controlling for the levels of RAPSV and
CEDV. This finding is consistent with the hypothesis that the
mechanisms by which hypertension and ischemia cause renal
damage are distinct from one another. Systolic pressures above
180 mm Hg were associated with a high (35.0%) cumulative
incidence of renal atrophy at two years. Diabetes and age were
also associated with an increased risk of renal shrinkage, but these
relationships were not statistically significant.
One shortcoming of this study is that renal length is a surrogate
endpoint for the true clinical endpoint of interest: renal function.
The primary objective of this study was to determine with
precision the relationship between renal ischemia and function.
Since the serum creatinine concentration is not expected to
change appreciably in an individual with unilateral renal atrophy,
it was necessary to use the kidney (and not the patient) as the unit
of analysis. The pole-to-pole renal length was chosen because it is
widely used in clinical practice and because it is simple to
measure. We did observe an association between atrophy as it was
defined in this study and changes in the serum creatinine concen-
tration, and a more formal analysis of the determinants of
declining renal function in this patient population is being under-
taken.
The results of this study have several potential clinical implica-
tions. The importance of adequate blood pressure control is
stressed, especially in this patient population whose hypertension
is frequently refractory to therapy with several agents. Since ACE
inhibitors are often the most effective medications for controlling
hypertension in this patient population, it was reassuring to find
no significant association between ACE inhibitor use and renal
atrophy, despite the theoretical reasons why such an association
might exist [23].
As was originally suggested by Goldblatt et al, the patient with
unilateral RAS appears to be at risk for bilateral renal damage-
from ischemia on the ipsilateral side and from hypertension (if not
well-controlled) on the contralateral side [1]. He hypothesized
that the kidney with ipsilateral high-grade RAS might be pro-
tected from the detrimental effects of hypertension. In fact, we
found no significant modification of the effect of systolic blood
pressure by the degree of RAS; the effect of hypertension on renal
atrophy was present in kidneys with and without high-grade
lesions. Furthermore, bilateral RAS is a frequent finding in this
patient population, and we have shown that the cumulative
incidence of renal artery disease progression from moderate
(, 60%) to high-grade ($ 60%) stenosis is 44% after two years
[24]. Thus, the effects of both ischemia and hypertension are
frequently encountered on both sides.
Whether the histologic changes in kidneys that decrease in
length are reversible after revascularization is unknown. Durable
technical results have been reported in several surgical and
radiologic series [25–29]. Yet, the effects of both surgical and
endovascular revascularization on azotemia associated with ath-
erosclerotic renal artery stenosis have been mixed [25, 27, 30].
Stable or improved renal function is documented in a small
majority of patients in these highly-selected case series, especially
when the pre-intervention impairment in renal function is not
severe [27], or has shown recent and rapid deterioration [31]. It is
possible that renal functional outcome can be maximized by the
proper selection of patients for revascularization before any
significant impairment in renal function has taken place.
Summary
This prospective study of patients with atherosclerotic renal
artery stenosis demonstrates that kidneys subjected to severe
ischemia and poorly controlled hypertension are at increased risk
of atrophy, and that the loss of renal mass correlates with
elevations in the serum creatinine concentration. Renal artery
duplex scanning is technically difficult, but has been successfully
applied in a small number of centers where technical expertise has
been developed. As this technique becomes more widely accepted
as a valid and reproducible clinical tool, it may play an important
role in the selection of patients for renal artery revascularization.
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APPENDIX
Abbreviations used in this article are: AAI, ankle arm index; ACE,
angiotensin converting enzyme; ARAS, atherosclerotic renal artery steno-
sis; CEDV, cortical end diastolic velocity; CI, cumulative index; CPSV,
cortical peak systolic velocity; DBP, diastolic blood pressure; EDR, end
diastolic ratio; PSV; peak systolic velocity; RAPSV, renal artery peak
systolic velocity; RAR, renal aortic ratio; RAS, renal artery stenosis; SBP,
systolic blood pressure.
REFERENCES
1. GOLDBLATT H, LYNCH J, HANZAL RF, SUMMERFILLE WW: Studies on
experimental hypertension I, the production of persistent elevation of
systolic blood pressure by means of renal ischemia. J Exp Med
59:347–379, 1934
2. JACOBSON HR: Ischemic renal disease: An overlooked clinical entity?
(Nephrology Forum) Kidney Int 34:729–743, 1988
3. DEAN RH, TRIBBLE RW, HANSEN KJ, O’NEIL E, CRAVEN TE,
REDDING JF II: Evolution of renal insufficiency in ischemic nephrop-
athy. Ann Surg 213:446–455, 1991
4. RIMMER JM, GENNARI FJ: Atherosclerotic renovascular disease and
progressive renal failure. Ann Intern Med 118:712–719, 1993
5. MCNEIL EA, HANSEN KJ, CANZANELLO VJ, PENNELL TC, DEAN RH:
Prevalence of ischemic nephropathy in patients with renal insuffi-
ciency. (abstract) Am Surg 58:485, 1992
6. KOHLER TR, ZIERLER RE, MARTIN RL, NICHOLLS SC, BERGELIN RO,
KAZMERS A, BEACH KW, STRANDNESS DE JR: Noninvasive diagnosis
of renal artery stenosis by ultrasonic duplex scanning. J Vasc Surg
4:450–456, 1986
7. TAYLOR DC, KETTLER MD, MONETA GL, KOHLER TR, KAZMERS A,
BEACH KW, STRANDNESS DE JR: Duplex ultrasound scanning in the
diagnosis of renal artery stenosis: A prospective evaluation. J Vasc
Surg 7:363–369, 1988
8. HOFFMANN U, EDWARDS JM, CARTER S, GOLDMAN ML, HARLEY JD,
ZACCARDI MJ, STRANDNESS DE JR: Role of duplex scanning for the
detection of atherosclerotic renal artery disease. Kidney Int 39:1232–
1239, 1991
9. BRANDT TD, NEIMAN HL, DRAGOWSKI MJ, BULAWA W, CLAYKAMP
G: Ultrasound assessment of normal renal dimensions. J Ultrasound
Med 1:49–52, 1982
10. EFRON B: The Jacknife, the Bootstrap, and other Resampling Plans.
Philadelphia, Society for Industrial and Applied Mathematics, 1982
11. DEAN RH, KIEFFER RW, SMITH BM, OATES JA, NADEAU JHJ,
HOLLIFIELD JW, DUPONT WD: Renovascular hypertension: Anatomic
and renal function changes during drug therapy. Arch Surg 116:1408–
1415, 1981
12. SCHREIBER MJ, POHL MA, NOVICK AC: The natural history of
atherosclerotic and fibrous renal artery disease. Urol Clin North Am
11:383–392, 1984
13. OLIN JW, PIEDMONTE MR, YOUNG JR, DEANNA S, GRUBB M, CHILDS
MB: The utility of duplex ultrasound scanning of the renal arteries for
diagnosing significant renal artery stenosis. Ann Intern Med 122:833–
838, 1995
14. HANSEN KJ, TRIBBLE RW, REAVIS SW, CANZANELLO VJ, CRAVEN TE,
PLONK GW JR, DEAN RH: Renal duplex sonography: Evaluation of
clinical utility. J Vasc Surg 12:227–236, 1990
15. GUZMAN RP, ZIERLER RE, ISAACSON JA, BERGELIN RO, STRANDNESS
DE JR: Renal atrophy and arterial stenosis. A prospective study with
duplex ultrasound. Hypertension 23:346–350, 1994
16. ZIERLER RE, BERGELIN RO, ISAACSON JA, STRANDNESS DE JR:
Natural history of atherosclerotic renal artery stenosis: A prospective
study with duplex ultrasonography. J Vasc Surg 19:250–258, 1994
17. KIDA H, YOSHIMURA M: Renal arterial disease-induced tubulo-
interstitial lesions. Nippon Rinsho 53:2034–2039, 1995 (in Japanese)
18. MORAN K, MULHALL J, KELLY D, SHEEHAN S, DOWSETT J, DERVAN P,
FITZPATRICK JM: Morphological changes and alterations in regional
intrarenal blood flow induced by graded renal ischemia. J Urol
148:1463–1466, 1992
19. GOB’E GC, AXELSEN RA, SEARLE JW: Cellular events in experimental
unilateral ischemic renal atrophy and in regeneration after contralat-
eral nephrectomy. Lab Invest 63:770–779, 1990
20. SABBATINI M, SANSONE G, UCCELLO F, DE NICOLA L, GILIBERTI A,
SEPE V, MARGRI P, CONTE G, ANDREUCCI VE: Functional versus
structural changes in the pathophysiology of acute ischemic renal
failure in aging rats. Kidney Int 45:1355–1361, 1994
21. TRUONG LD, FARHOOD A, TASBY J, GILLUM D: Experimental chronic
renal ischemia: Morphologic and immunologic studies. Kidney Int
41:1676–1689, 1992
22. SHANLEY PF: The pathology of chronic renal ischemia. Semin Nephrol
16:21–32, 1996
23. HRICIK DE, DUNN MJ: Angiotensin-converting enzyme inhibitor-
induced renal failure: Causes, consequences, and diagnostic uses.
J Am Soc Nephrol 1:845–858, 1990
24. ZIERLER RE, BERGELIN RO, DAVIDSON RC, CANTWELL GAB K,
POLISSAR NL, STRANDNESS DE JR: A prospective study of disease
progression in patients with atherosclerotic renal artery stenosis. Am J
Hypertens 9:1055–1061, 1996
25. HALLETT JW JR, FOWL R, O’BRIEN PC, BERNATZ PE, PAIROLERO PC,
CHERRY KJ JR, HOLLIER LH: Renovascular operations in patients
with chronic renal insufficiency: Do the benefits justify the risks? J
Vasc Surg 5:622–627, 1987
26. HANSEN KJ, STARR SM, SANDS RE, BURKART JM, PLONK GW JR,
DEAN RH: Contemporary surgical management of renovascular dis-
ease. J Vasc Surg 16:319–331, 1992
27. CAMBRIA RP, BREWSTER DC, L’ITALIEN GJ, GERTLER JP, ABBOTT
WM, LAMURAGLIA GM, MONCURE AC, VIGNATI J, BAZARI H, FANG
LT, ATAMIAN S: Renal artery reconstruction for the preservation of
renal function. J Vasc Surg 24:371–380, 1996
28. BLUM U, KRUMME B, FLUGEL P, GABELMANN A, LEHNERT T, BUIT-
RAGO TELLEZ C, SCHOLLMEYER P, LANGER M: Treatment of ostial
renal-artery stenoses with vascular endoprostheses after unsuccessful
balloon angioplasty. N Engl J Med 336:459–465, 1997
29. JENSEN G, ZACHRISSON BF, DELIN K, VOLKMANN R, AURELL M:
Treatment of renovascular hypertension: One year results of renal
angioplasty. Kidney Int 48:1936–1945, 1995
30. ERDOES LS, BERMAN SS, HUNTER GC, MILLS JL: Comparative
analysis of percutaneous transluminal angioplasty and operation for
renal revascularization. Am J Kidney Dis 27:496–503, 1996
31. HANSEN KJ, THOMASON RB, CRAVEN TE, FULLER SB, KEITH DR,
APPEL RG, DEAN RH: Surgical management of dialysis-dependent
ischemic nephropathy. J Vasc Surg 21:197–209, 1995
Caps et al: Renal atrophy and arterial stenosis742
